TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01269255
Drug: TS-1 with Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SP CCRT(= TS-1 with Cisplatin concurrent radiation therapy)~* Step 1: Chemotherapy; TS-1/CDDP #2 cycles~* Step 2: Chemoradiotherapy; CCRT with weekly TS-1/CDDP~* Step 3: Surgery therapy
Study: NCT00423852
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00423852
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00423852
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00363194
Drug: Pazopanib (GW786034)
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib (GW786034)
Study: NCT05824390
Drug: rituximab group
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab is a human-mouse chimeric monoclonal antibody specifically targeting B cell surface antigen CD20. CD20 may act as a calcium channel to play a certain signal role and participate in the regulation of B cell maturation and differentiation. Once combined with CD20, RTX consumed CD20 + B fines through antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and direct induction of apoptosis. Recent studies have shown that B cell depletion therapy has a certain effect on many autoantibodies-mediated kidney diseases ( such as membranous nephropathy, lupus nephritis, etc. ). Therefore, rituximab combined with CD20 antigen on the surface of B cells can exhaust B cells that produce antibodies and play a therapeutic role by reducing antibody production, so this therapy also has potential therapeutic value for IgAN patients.
Study: NCT04106843
Drug: Lutetium Lu 177 Dotatate
Normalized name: Lutetium Lu 177 dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03772106
Drug: Propofol Fresenius
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propolipid 1% : IV
Study: NCT01503983
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)
Study: NCT01503983
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
Study: NCT03106298
Drug: Iron Sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
Study: NCT01837290
Drug: dexmedetomidine infusion for premedication
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
Study: NCT01837290
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous Midazolam 0.02 mg/kg for premedication
Study: NCT01837290
Drug: Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine injection for spinal block
Study: NCT03772106
Drug: sevorane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sevorane Quick fill (sevoflurane) : inhalation
Study: NCT03375814
Drug: Crocin
Normalized name: CROCIN
DrugBank: Crocin (DB11874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group (osteoarthritic patients) can receive crocin with conventional therapy
Study: NCT00986115
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
Study: NCT04575675
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10mg once daily
Study: NCT04575675
Drug: Sacubitril-Valsartan
Normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sacubitril-Valsartan, maximal tolerated dosage
Study: NCT04575675
Drug: Mineralocorticoid Receptor Antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Mineralocorticoid receptor antagonist, including spironolactone or eplerenone
Study: NCT00309920
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00309920
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00875849
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03333083
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir (1200 mg once a day)
Study: NCT03333083
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (300 mg once a day)
Study: NCT04208347
Drug: Apatinib 250mg
Normalized name: LAPATINIB 250MG TAB
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 250mg
Study: NCT04208347
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg
Study: NCT04208347
Drug: S-1, Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: S-1, Oxaliplatin, q3w
Study: NCT04208347
Drug: Apatinib 500mg
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500mg
Study: NCT00637832
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02351323
Drug: Glutamine (Pharmacological doses)
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 grams/day of glutamine for 12-14 months
Study: NCT01767129
Drug: AVP-923-45
Normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule twice daily for 14 days
Study: NCT01110720
Drug: Davunetide
Normalized name: Davunetide
DrugBank: Davunetide (DB12613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Davunetide Nasal Spray 30 mg BID IN 52 weeks
Study: NCT02154477
Drug: intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: insulin
Study: NCT01172639
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine tablet
Study: NCT01172639
Drug: Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide tablet
Study: NCT01172639
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone tablet
Study: NCT04310527
Drug: Enasidenib
Normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enasidenib
Study: NCT00809341
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
Study: NCT00809341
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/day on Days 1-5 of each cycle as part of R-CHOP.
Study: NCT00809341
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2000 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
Study: NCT00809341
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given on Day 2 of each cycle as part of R-CHOP. Dosed according to renal function.
Study: NCT00809341
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m\^2/day on Days 1-3 of each cycle as part of R-CHOP.
Study: NCT02127489
Drug: 1 mL/kg bupivacaine 0.25%.
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
Study: NCT01843452
Drug: MITOMYCIN
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2 IV administered over 15 min infusion on days 1 and 29.
Study: NCT01296412
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg tablet, orally, once daily.
Study: NCT04421313
Drug: Dietary Fiber Supplementation
Normalized name: fiber
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g of inulin or of maltodextrin in powder, to dilute in water once daily, during 1 month. Given in pre-weighted pots (one pot per day, similar color and aspect)
Study: NCT02606383
Drug: Dapaconazole
Normalized name: Dapaconazole
DrugBank: Dapaconazole (DB11985)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02606383
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04061863
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks
Study: NCT00276900
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04970381
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.
Study: NCT01296412
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
Study: NCT01296412
Drug: glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
Study: NCT01296412
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin tablets at a dose of ≥1500 mg per day
Study: NCT01471067
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
Study: NCT01471067
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.
Study: NCT01471067
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).
Study: NCT03875079
Drug: RO6874281
Normalized name: RO6874281
DrugBank: Simlukafusp alfa (DB16092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part I Safety Run in:~Cohort 1.1: RO6874281 will be administered by intravenous (IV) infusion; 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (i.e. 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.~Cohort 1.2: RO6874281 will be administered by IV infusion via an induction and maintenance phase; 10 mg (QW) every week for 3 weeks followed by 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (6 weeks) to confirm safety of the proposed dose and schedule to be used in Part III of this study.~Part II Expansion: RO6874281 will be administered by IV infusion; 10 mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohort 1.1 outcome).~Part III Expansion: RO6874281 will be administered by IV infusion; 10 mg (QW) every week or 10mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes) in either a Q3W or QW/Q3W schedule.
Study: NCT03875079
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part I Safety Run in (Cohorts 1.1 and 1.2): Pembrolizumab will be administered by IV; 200 mg Q3W and will be observed over 2 administration cycles (i.e. 6 weeks).~Part II Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohort 1.1 outcome)~Part III Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes)
Study: NCT01471067
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.
Study: NCT01471067
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 by vein on Day -10 for B cell malignancy.
Study: NCT01471067
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/Kg by vein on Day -4.~1.75 mg/Kg by vein on Day -3.
Study: NCT01155661
Drug: LY2216684 (edivoxetine)
Normalized name: Edivoxetine
DrugBank: Edivoxetine (DB09184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 to 18 milligrams (mg), administered orally, once daily for 54 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
Study: NCT01155661
Drug: SSRI
Normalized name: SSRI - Selective serotonin re-uptake inhibitor
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
Study: NCT02579356
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02579356
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00616746
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.0 microg/kg/min IV x 10 minutes
Study: NCT02477449
Drug: istaroxime
Normalized name: Istaroxime
DrugBank: Istaroxime (DB06157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
Study: NCT00702416
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Block induction \[1% (wt/vol) solution\]:~20 ml (200 mg)~Postoperative analgesia \[0.2% (wt/vol) solution\]:~* Background infusion: 4 ml/h (8 mg/h)~* Incremental on-demand dose: 2 ml (4 mg)~* Lockout time: 15 min
Study: NCT00702416
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 g iv q8h
Study: NCT00702416
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg im prn q1h (in the postoperative period)
Study: NCT04488367
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/kg IV TXA in the ED, repeat doses before skin incision and in PACU
Study: NCT00362947
Drug: LMWH parnaparin subcutaneously
Normalized name: parnaparin
DrugBank: Parnaparin (DB09260)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02806596
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).
Study: NCT03738397
Drug: Placebo to dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo administered as a subcutaneous injection
Study: NCT03738397
Drug: Placebo to upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet
Study: NCT04402203
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Favipiravir 200 mg (Favipira) tablet will be given orally. Day 1: Tablet Favipiravir 1600 mg twice daily Days 2-Days 10: Tablet Favipiravir 600 mg twice daily.
Study: NCT01975636
Drug: E2609
Normalized name: Elenbecestat
DrugBank: Elenbecestat (DB15391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
Study: NCT03745586
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 3: Tocilizumab infusion (8mg/kg body-weight) Day 10- week 52: Tocilizumab s.c. injections (162mg) in weekly intervals
Study: NCT02894905
Drug: AL-335
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with various degrees of impaired renal function (mild \[Cohort 1\], moderate \[Cohort 2\], severe \[Cohort 3\]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2\*400-mg tablets).
Study: NCT01664897
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00069277
Drug: E7389
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04419649
Drug: KER-050
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KER-050 administered subcutaneously every 4 weeks for up to 24 cycles. Eligible participants may be able to continue to receive subcutaneously administered KER-050 after completing 24 cycles in a Long-Term Extension.
Study: NCT04023149
Drug: recombinant human interleukin-2 (rhIL-2)
Normalized name: Recombinant human interleukin-2
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: rhIL-2; Pharmaceutical form: solution; Route of administration: oral gargle.
Study: NCT03679767
Drug: Retifanlimab
Normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retifanlimab administered intravenously at 500 mg every 4 weeks
Study: NCT01988896
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered at a fixed dose as specified via IV infusion.
Study: NCT01988896
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.
Study: NCT03653832
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation.
Study: NCT01471067
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
Study: NCT01471067
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30 mg/m\^2 IV Day -7 to Day -4;